DRG Epidemiology's coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Following the introduction of the anti-VEGF therapies over a decade ago, the wet AMDmarket has been dominated by three therapies—Roche/Genentech/Novartis’s Lucentis, approved for wet AMD,…
There are limited treatment options for patients with advanced/metastatic, triple-negative breast cancer because commonly used treatments in other breast cancer segments (i.e., hormonal therapies…
Abstract: Hepatocellular carcinoma is the most common form of liver cancer. It is the seventh-most-common type of cancer worldwide and the third-most-common cause of cancer death worldwide. Most…
From disease basics to insightful analysis of market dynamics, Thyroid Carcinoma | Niche Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing…
Antibody drug conjugates (ADCs) are a class of drug therapies that combine the targeting abilities of monoclonal antibodies with the cancer-killing activities of cytotoxic agents. ADCs can…
Treatment of moderate to severe cancer pain will continue to be dominated by opioid analgesics for the foreseeable future. However, with the widespread epidemic of opioid abuse and misuse in the…
The approval of the first oncolytic viral therapy, Imlygic, in the United States and EU5 in 2015 and 2016, respectively, marks a significant milestone for cancer vaccines and viral therapies,…
The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However, the barriers to entry are…
Breast cancer requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, chemotherapies, and targeted therapies. Treatment decisions are influenced by disease stage,…
The drug treatment of prostate cancer has evolved rapidly over the last few years—the metastatic castrate-resistant prostate cancer (mCRPC) setting has become crowded and competitive following…
Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansions…
Tens of thousands of Brazilian and Mexican men are diagnosed with prostate cancer every year. In recent years, there have been multiple clinical advances in the field, with new therapies offering…
Gastric and gastroesophageal junction (GEJ) adenocarcinoma is characterized by poor prognosis. Japan has the highest incidence of gastric and GEJ adenocarcinoma among the markets under study,…
Consolidation within the oncology provider community, including hospital acquisitions of oncology practices and oncology practices joining together, is changing the dynamics in the relationship…